The incidence of RP-ILD is lesser in Caucasian populations, with 38% to 73% of the patients with anti-MDA5 antibody-positive DM having ILD and 20% to 57% having RP-ILD.[3] In East Asia, patients with anti-MDA5 antibody-positive DM often have RP-ILD and require at least triple therapy including glucocorticoids, cyclophosphamide, and tacrolimus at an early stage. Here, IFIH1 is linked to dermatomyositis.